Xenetic Biosciences
XBIO
9 hedge funds and large institutions have $212K invested in Xenetic Biosciences in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
241% more capital invested
Capital invested by funds: $62K → $212K (+$150K)
80% more funds holding
Funds holding: 5 → 9 (+4)
2.2% more ownership
Funds ownership: 0.97% → 3.16% (+2.2%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
S
Sachetta
Lynnfield,
Massachusetts
|
+$68.4K |
| 2 |
Renaissance Technologies
New York
|
+$62.4K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.72K |
| 4 |
JP Morgan Chase
New York
|
+$787 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$71 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$741 |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$390 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
S
1
Sachetta
Lynnfield,
Massachusetts
| $75K | +$68.4K | +17,371 | New |
|
|
2
Renaissance Technologies
New York
| $68.5K | +$62.4K | +15,850 | New |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $52.1K | -$390 | -99 | -0.8% |
|
|
JEST
4
JTC Employer Solutions Trustee
St Helier,
Jersey
| $12K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $2.99K | +$2.72K | +692 | New |
|
|
6
JP Morgan Chase
New York
| $876 | +$787 | +200 | New |
|
|
7
Bank of America
Charlotte,
North Carolina
| $126 | +$71 | +18 | +164% |
|
|
DWM
8
Darwin Wealth Management
Tampa,
Florida
| $9 | +$8 | +2 | New |
|
9
Morgan Stanley
New York
| $4 | – | – | – |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$741 | -182 | Closed |
|
XBIO Hedge Fund Activity: Q3 2024 in Review
9 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q3 2024, worth a combined $212K — up 241% from $62K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new XBIO positions and 1 closed out — a net gain of 4 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Sachetta, opening a new position worth an estimated $68.4K. The largest seller was UBS Group, exiting entirely with an estimated $741 sold.
- 9 institutional investors held Xenetic Biosciences (XBIO) as of Q3 2024, up from 5 in Q2 2024.
- Funds reported $212K of Xenetic Biosciences stock for Q3 2024, up 241% quarter-over-quarter.
- 5 funds opened new Xenetic Biosciences positions in Q3 2024 and 1 closed out, a net change of +4 holders.
- The largest Xenetic Biosciences buyer in Q3 2024 was Sachetta, an estimated $68.4K added.
- The largest Xenetic Biosciences seller in Q3 2024 was UBS Group, an estimated $741 sold.
Based on aggregated 13F filings for Q3 2024.